Immunotherapy, which involves adapting immune cells to destroy specific cellular targets, has made a name for itself treating cancer. But over the last few years, a handful of research groups have advanced T-cell therapies for viral infections, and are now on the cusp of commercialization. “Using T cells to target infectious diseases is not a new field,” says immunologist Michael Keller of Children’s National Hospital in Washington, D.C., “but it’s something that’s expanding a great deal.” Continue reading Antiviral Immunotherapy Comes of Age